Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder	Recruiting	Phase 2	2025-03-06		NCT05704621

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Asia-Pacific Gynecologic Oncology Trials Group	4
Boryung Pharmaceutical Co., Ltd	32
Chong Kun Dang Pharmaceutical Corp.	4
Japanese Gynecologic Oncology Group	4
KGOG: Korean Gynaelogical Onology Group, Korea	1
Korea University Guro Hospital	29
Yonsei University	213

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Severance Hospital	Seoul	South Korea	62